Biolexis Therapeutics, Inc. ( ), a clinical-stage therapeutics company pioneering next-generation treatments for metabolic and muscle-wasting diseases, today announced the initiation of Phase I ...

"Let's say you wake up really hungry," says Lembas CTO Dr. Zohar Barbash. "You take the peptide and feel like you have just ...

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

More than 65% of participants reached an A1C level below 6.5%. Orforglipron is the first small-molecule GLP-1 therapy to successfully complete a phase 3 trial. Eli Lilly plans to submit for ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.